New drug combo tested to stall advanced prostate cancer before surgery

This study tested if adding a drug called axitinib to standard hormone-blocking therapy before surgery could better control prostate cancer that had spread to lymph nodes. It involved 73 men who were randomly assigned to receive either the standard therapy alone or the standard therapy plus axitinib for four months before undergoing surgery. The main goal was to see which group had a longer period without their cancer getting worse after the operation.